When the development of biopharmaceuticals is right, the growth space of upstream equipment and consumables will be opened

In recent years, under the resonance of multiple factors such as the continuous release of favorable policies, the emergence of talents, and the increase in capital, China's biopharmaceutical industry has performed actively.
In addition, the Science and Technology Innovation Board and the Hong Kong Stock Exchange have relaxed the IPO conditions for pharmaceutical and biotechnology companies.
More and more of startups have sprung up
.
It can be said that the development of biopharmaceuticals is at the right time
.
In the long run, with the advancement of medical insurance cost control, the pharmaceutical industry will accelerate innovation.
At the same time, under the background of population aging and consumption upgrading, there is still a large demand in the field of life and health, which is expected to promote the rapid development of the biopharmaceutical industry
.
The industry predicts that by 2025, the size of the biopharmaceutical market alone in China's biopharmaceutical field will exceed the 800 billion mark
.
When the development of biopharmaceuticals is just in time, the growth space of upstream equipment and consumables will be opened (Photo source: Pharmaceutical Network) It is worth mentioning that at present, China has carried out six batches of centralized procurement, and the scope of centralized drug procurement has also expanded from drugs and consumables to detection reagents, biological medicine
.
On November 26, 2021, the sixth batch of national drug centralized insulin special centralized procurement work was launched.
The average price of the winning products was reduced by 48%, and more products fell by more than 70%
.
The industry believes that under the trend of price reduction of biological products, drug companies will bring challenges to cost control and demand for stable production capacity.
The two major changes will accelerate the transfer of the upstream industry chain to domestic production
.
The upstream of biopharmaceuticals mainly includes two major links, R&D and production.
In the R&D link, the current upstream equipment, reagents and consumables products are accelerating domestic substitution, especially in the field of in vitro diagnostics.
In recent years, domestic strength has gradually become prominent, and brand influence is constantly improving
.
In the production of biological drugs, including production and purification, detection and packaging, etc.
, a series of equipment and consumables are also involved, such as bioreactors, chromatography columns, filters, light inspection machines and other equipment, as well as culture medium, chromatography Filling, filter membrane and other consumables
.
The industry pointed out that the production of biological drugs is inseparable from the support of some large-scale equipment, such as light inspection machines, freeze dryers, filling and packaging lines,
etc.
These equipment often require high capital investment.
As labor costs and production costs continue to rise, biopharmaceutical companies will face the challenge of cost control, which will bring opportunities to domestic consumables and equipment companies.
It is expected that the domestic high-end equipment consumables market will continue to growth, accelerating the pace of import substitution
.
At the same time, biopharmaceutical equipment consumables are also facing the challenge of upgrading
.
For example, in the field of bioreactors, disposable bioreactors are replaceable compared to traditional stainless steel bioreactors due to their better flexibility, low cost and short time consumption
.
The data shows that the domestic disposable reactor market has grown significantly in recent years.
It is estimated that by 2027, the disposable reactor market will reach 1.
52 billion yuan
.
At present, in the field of localization of biopharmaceutical equipment consumables, some representative domestic enterprises have emerged, such as Tofflon, Morison International, Chutian Technology,
etc.
Entering 2022, many biopharmaceutical upstream equipment and consumables companies have released new achievements in scientific and technological research
.
For example, just recently, Lechun Bio has successively launched biopharmaceutical process films, reaction bags, reactors and other products, of which the films are self-developed and produced, which will add a heavy touch to the localization of biopharmaceutical consumables
.
Although the market space for high-end biopharmaceutical equipment is considerable, it should be noted that due to the high threshold of high-end biopharmaceutical equipment consumables industry, compared with new entrants, equipment and consumables companies with advanced layout, strong R&D strength and rich experience will be more capable advantage, and is expected to embrace more opportunities for import substitution
.
According to data, according to the estimated growth rate in the next five years, it is estimated that the total market size of domestic biopharmaceutical equipment consumables will exceed 30 billion in 2025.
It is expected that by 2025, the average localization rate will increase from below 20% to 30%-40%.
Around, it is speculated that domestic enterprises will have a market share of nearly 10 billion by then
.